Health-related quality of life (HRQoL) with adjuvant nivolumab (NIVO) vs   placebo (PBO) after radical resection for high-risk muscle-invasive   urothelial carcinoma (MIUC): results from the phase 3 CheckMate 274   trialep138

Document type:: Meeting Abstract
Author(s):: Gschwend, J. E.; Bajorin, D.; Galsky, M.; Broughton, E.; Braverman, J.; Koon, H.; Maira-Arce, M.; Hamilton, M.; Shi, L.; Guo, S.; Witjes, J. A.
Title:: Health-related quality of life (HRQoL) with adjuvant nivolumab (NIVO) vs placebo (PBO) after radical resection for high-risk muscle-invasive urothelial carcinoma (MIUC): results from the phase 3 CheckMate 274 trialep138
Journal title abbreviation:: Oncology Research and Treatment
Year:: 2021
Journal volume:: 44 Suppl 2
Pages contribution:: 263-264
Print-ISSN:: 2296-5270
TUM Institution:: Urologische Klinik und Poliklinik
BibTeX

Occurrences: